OptimizeRx Corporation
OPRXNASDAQHealthcare● Active
$5.17
+$0.06(+1.17%)
Market Cap$97015438
P/E Ratio—
52W High$22.25
52W Low$4.57
OptimizeRx Corporation (OPRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OPRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
$0.14
Est. $0.01 · +1300.0%
Revenue
$0.02B
Est. $0.02B · +5.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 9-Quarter EPS Beat Streak
OPRX reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.11 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 12, 2026 | $0.01 | $0.14 | +1300.0% | $0.02B | $0.02B | +5.9% |
| ▲ Q1 FY2026 | Mar 5, 2026 | $0.23 | $0.51 | +121.7% | $0.03B | $0.03B | +4.3% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.03 | $0.20 | +566.7% | $0.03B | $0.03B | -15.7% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.03 | $0.24 | +700.0% | $0.03B | $0.02B | +22.5% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.11 | $0.08 | +172.7% | $0.02B | $0.02B | +17.4% |
| ▲ Q1 FY2025 | Mar 12, 2025 | $0.25 | $0.30 | +20.0% | $0.03B | $0.02B | +72.1% |
| ▲ Q4 FY2024 | Nov 13, 2024 | $0.06 | $0.12 | +100.0% | $0.02B | $0.03B | -29.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
$0.14
EPS Est.
$0.01
EPS Surpr.
+1300.0%
Revenue
$0.02B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
$0.51
EPS Est.
$0.23
EPS Surpr.
+121.7%
Revenue
$0.03B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.20
EPS Est.
$0.03
EPS Surpr.
+566.7%
Revenue
$0.03B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.24
EPS Est.
$0.03
EPS Surpr.
+700.0%
Revenue
$0.03B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.08
EPS Est.
-$0.11
EPS Surpr.
+172.7%
Revenue
$0.02B
Q1 FY2025
Mar 12, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.25
EPS Surpr.
+20.0%
Revenue
$0.03B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
$0.12
EPS Est.
$0.06
EPS Surpr.
+100.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.51 | $0.55 | $0.61 | 2 |
| Q3 FY2027 | $0.28 | $0.30 | $0.33 | 1 |
| Q2 FY2027 | $0.10 | $0.10 | $0.11 | 1 |
| Q1 FY2027 | $0.12 | $0.13 | $0.14 | 2 |
| Q4 FY2026 | $0.40 | $0.43 | $0.48 | 2 |
| Q3 FY2026 | $0.18 | $0.24 | $0.29 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +1300.0% | $6.21 | $6.34 | +2.09% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +121.7% | $7.87 | $7.53 | -4.32% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +566.7% | $19.16 | $18.94 | -1.15% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +700.0% | $12.48 | $12.84 | +2.88% |
| ▲ Q2 FY2025 | May 12, 2025 | +172.7% | $9.99 | $9.20 | -7.91% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +20.0% | $4.14 | $6.28 | +51.69% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +100.0% | $5.84 | $6.15 | +5.31% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +128.6% | $8.28 | $8.85 | +6.88% |
Q2 FY2026+2.09%
Report Date
May 12, 2026
EPS Beat/Miss
+1300.0%
Price Before
$6.21
Price After
$6.34
Q1 FY2026-4.32%
Report Date
Mar 5, 2026
EPS Beat/Miss
+121.7%
Price Before
$7.87
Price After
$7.53
Q4 FY2025-1.15%
Report Date
Nov 6, 2025
EPS Beat/Miss
+566.7%
Price Before
$19.16
Price After
$18.94
Q3 FY2025+2.88%
Report Date
Aug 7, 2025
EPS Beat/Miss
+700.0%
Price Before
$12.48
Price After
$12.84
Q2 FY2025-7.91%
Report Date
May 12, 2025
EPS Beat/Miss
+172.7%
Price Before
$9.99
Price After
$9.20
Q1 FY2025+51.69%
Report Date
Mar 12, 2025
EPS Beat/Miss
+20.0%
Price Before
$4.14
Price After
$6.28
Q4 FY2024+5.31%
Report Date
Nov 13, 2024
EPS Beat/Miss
+100.0%
Price Before
$5.84
Price After
$6.15
Q3 FY2024+6.88%
Report Date
Aug 8, 2024
EPS Beat/Miss
+128.6%
Price Before
$8.28
Price After
$8.85
Avg Beat Reaction+6.93%
Beat Rate8 / 8 quarters
Largest Move+51.69% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OPRX ends December
OptimizeRx Corporation (OPRX) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $0.14 — beating the analyst consensus of $0.01 by +1300.0%. OPRX has beaten EPS estimates for 9 consecutive quarters. The next OPRX earnings date is expected around September 1, 2026.
Each quarter, investors track OPRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OPRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OPRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OPRX earnings · 5 questionsOptimizeRx Corporation's next earnings report is expected around September 1, 2026. OPRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OPRX historically reports after market close (AMC).
OPRX earnings datewhen is OPRX earningsOPRX next earnings datewhen does OPRX report earningsOPRX earnings calendar
▸ Source: FMP · OptimizeRx Corporation SEC filings · US GAAP · OptimizeRx Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026